This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Arrowhead Announces New Study Demonstrating Rapid Improvement In Pro-Diabetic Metabolic Markers With Anti-Obesity Drug Candidate, Adipotide®

Stocks in this article: ARWR

Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced the publication of data demonstrating that its anti-obesity drug candidate, Adipotide, induces rapid metabolic changes with implications for Type II diabetes. An independent laboratory reported that obese mice treated with Adipotide displayed significantly improved insulin sensitivity, improved glucose tolerance, and a reduction in serum triglycerides after only 2-3 days of treatment. These effects occurred independent of and prior to Adipotide-induced weight loss. The findings, published online ahead of print in the Journal of the American Diabetes Association ( Diabetes Epub June 25, 2012 ), are presented in a paper titled "Rapid and weight-independent improvement of glucose tolerance induced by a peptide designed to elicit apoptosis in adipose tissue endothelium." The research team is led by Director of the Cincinnati Diabetes and Obesity Center, Dr. Randy Seeley.

"A large amount of data generated over the past eight years across multiple laboratories have suggested that Adipotide is a unique and potentially powerful agent against the obesity epidemic,” said Dr. Christopher Anzalone, President and Chief Executive Officer of Arrowhead. “This new study suggests that it may also be a powerful agent against obesity’s sister epidemic, Type II diabetes. The extent and speed of the effects reported by Dr. Seeley’s group are truly striking. We have always been excited about this new suite of anti-obesity drug candidates for many reasons, including: the unique mode of action; rapid weight loss seen in rodents and non-human primates; and data suggesting that animals have decreased appetites while they are losing weight. The current study adds a new dimension to the program and expands the potential reach to include Type II diabetes. We are looking forward to the results of the first human study."

Unlike many anti-obesity drugs in development that attempt to control appetite by targeting the central nervous system, Adipotide acts directly on fat, or Adipose, tissue by disrupting the blood supply to fat cells. Prior studies across multiple animal models have suggested that this leads to weight loss in two primary ways. First, as fat cells are deprived of blood supply they are metabolized by the body. Second, altering the vasculature feeding excess white fat changes metabolic parameters that lead to decreased food intake. The current study takes this a step further and indicates that the metabolic changes may have profound implications for Type II diabetes. Researchers observed that Adipotide treatment “appears to improve white adipose tissue (WAT) function…even while adipose mass is reduced” and “results in improved WAT hormone secretion, plasma lipids, plasma amino acids and WAT gene expression. While counter-intuitive, these data support the hypothesis that WAT function is improved rather than impaired by inhibiting WAT vasculature and that this contributes to the improved glucose regulation.”

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs